-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Pr6YYido51Bm9VXawXYJwZskLE2qr6ZHytk/i3vH2II1wjXtjijSNsUeV02oS0Xj ViPWD6ZRmkY95NhLXDdLkg== 0000950123-05-015141.txt : 20051223 0000950123-05-015141.hdr.sgml : 20051223 20051223080018 ACCESSION NUMBER: 0000950123-05-015141 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051223 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20051223 DATE AS OF CHANGE: 20051223 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 051283987 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER RD CITY: TARRYTOWN STATE: NY ZIP: 10591-6707 BUSINESS PHONE: 9143477000 8-K 1 y15894e8vk.htm FORM 8-K 8-K
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): December 23, 2005 (December 19, 2005)
REGENERON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
         
New York   000-19034   133444607
(State or other   (Commission File Number)   (I.R.S. Employer
jurisdiction of       Identification Number)
incorporation)        
   
777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
(Address of principal executive offices) (Zip Code)
(914) 347-7000
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 1.01   Entry into a Material Definitive Agreement
On December 19, 2005, the Compensation Committee of the Board of Directors of Regeneron Pharmaceuticals, Inc. (the “Company”) approved the following 2006 annual salaries and year-end 2005 cash bonus awards (paid in January 2006) to the specified named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission) of the Company:
                     
    Name/Title   2006 Salary (% increase from 2005)   Cash Bonus
 
  Leonard S. Schleifer, M.D., Ph.D.   $ 685,000  (2.9%)   $ 340,000  
 
  President & Chief Executive Officer                
 
                    
 
  George D. Yancopoulos, M.D., Ph.D.   $ 544,300  (4.5%)   $ 280,000  
 
  Executive Vice President, Chief                
 
  Scientific Officer and President,                
 
  Regeneron Research Laboratories                
 
                    
 
  Murray A. Goldberg   $ 374,300  (5.0%)   $ 179,700  
 
  Senior Vice President, Finance                
 
  & Administration, Chief Financial                
 
  Officer, Treasurer, and Assistant Secretary                
 
                    
 
  Neil Stahl, Ph.D.   $ 348,400  (4.5%)   $ 139,400  
 
  Senior Vice President, Preclinical                
 
  Development and Biomolecular Science                
 
                    
 
  Randall G. Rupp, Ph.D.   $ 339,100  (4.5%)   $ 125,500  
 
  Senior Vice President, Manufacturing                
 
  Operations                
     Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  REGENERON PHARMACEUTICALS, INC.
 		  
Dated: December 23, 2005  By:   /s/ Stuart Kolinski    
    Stuart Kolinski   
    Vice President and General Counsel   
 

2

-----END PRIVACY-ENHANCED MESSAGE-----